AN6.F Stock Analysis
AN
Uncovered
AnaptysBio Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 96 full-time employees. The company went IPO on 2017-01-26. The company is focused on developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases. Its product candidate pipeline includes Rosnilimab, which is designed to suppress aberrant T cell driven inflammation by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; ANB032, which is designed to augment BTLA signaling that is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation; ANB033, which targets CD122, the common beta subunit shared by the IL-15 and IL-2 receptors; Imsidolimab, which inhibits the interleukin-36 receptor (IL-36R) and is developed for the treatment of generalized pustular psoriasis (GPP), and Etokimab, which inhibits IL-33 function and acts upstream of key cell types involved in atopy and the subsequent release of Th2 cytokines.